SpyGlass Pharma Stock (NASDAQ:SGP)


OwnershipFinancialsChart

Previous Close

$21.18

52W Range

$17.06 - $32.44

50D Avg

$21.40

200D Avg

$23.66

Market Cap

$723.83M

Avg Vol (3M)

$96.03K

Beta

-0.34

Div Yield

-

SGP Company Profile


SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,489

IPO Date

Jan 08, 2008

Website

SGP Performance


SGP Financial Summary


Dec 25
Revenue-
Operating Income$-41.45M
Net Income$-39.87M
EBITDA$-40.84M
Basic EPS$-1.19
Diluted EPS$-1.19

Fiscal year ends in Dec 25 | Currency in USD